ClinicalTrials.gg
RecruitingNCT05973851INTENSIFY MDDUpdated Sep 26, 2025

The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.

A Phase 3 interventional study of Esketamine Nasal Product and Ketamine Hydrochloride in Major Depressive Disorder and Treatment Resistant Depression, sponsored by Dr. Inge Winter. Recruiting at 12 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by Dr. Inge Winter · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
418
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 100 studies testing escitalopram in Depressive Disorder, Major — 7 open to participants now, 7 under way, 1 of them phase 3. Escitalopram · Depressive Disorder, Major.

Planned enrollment
15th of 99
418 · median 80
Started
2024
the only one that year
Phase 3
18 of 100
1 open now
Registered
95th of 100
by date
Lead sponsor
2 of 100
Dr. Inge Winter

Among the 100 studies testing escitalopram in Depressive Disorder, Major, this one is the 15th largest by planned enrollment of the 99 interventional ones that give a count, is the only one that started in 2024, is one of 18 in phase 3, and was the 95th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

7 of the 100 studies testing escitalopram in Depressive Disorder, Major are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 100 studies testing escitalopram in Depressive Disorder, Major, or all of them as a file.
02

Study summary

Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available and prescribing medication is a process of trial-and-error. Guidelines do not explicitly advise on the order in which antidepressant medication should be prescribed. The choice of antidepressant should be tailored to the patient, while involving the patient in the decision-making process. In general, the choice for the first- and second-line treatment will be a second-generation antidepressant. Recently, esketamine nasal spray (intranasal (IN) administration) was approved for patients with treatment-resistant MDD (TRD). A patient is diagnosed with TRD when having used two antidepressants in sufficient duration and adequate dose without sufficient effect. TRD is associated with a negative impact on quality of life, higher risk for hospitalisations and suicide, comorbidities, poorer social and occupational functioning and a high carer burden. The efficacy of intranasal use of esketamine has been demonstrated in MDD subjects with treatment-resistant symptoms but also in subjects with non-treatment resistant depression, and is approved by the FDA and EMA as a third-line treatment. Besides the registered esketamine nasal spray, which is not available in all countries to all patients because of the high costs, off-label utilization of (es)ketamine infusions (IV) is growing extensively over time to treat TRD. Research conducted so far indicates an unequivocal initial substantial response to (es)ketamine IV in MDD populations, regardless of whether or not patients suffer from treatment resistant MDD. However, until now, there has not been a study investigating this in a sufficiently large population. This may be a unique opportunity to potentially prevent patients progressing into a treatment resistant illness stage. The potential implications of the results of the current study are the prevention of unnecessary trials of ineffective treatments, reducing subject burden substantially, as well as a reduction of healthcare and societal costs.

Read the detailed description

Rationale Over 28 million people suffer from current depressive disorder in the European Union. Major depressive disorder (MDD) is one of the most common psychiatric illnesses. The symptoms cause clinically significant distress or impairment in social, occupational, and other important areas of functioning. To treat MDD, there are several antidepressants available and prescribing medication is a process of trial-and-error. Guidelines do not explicitly advise on the order in which antidepressant medication should be prescribed. The choice of antidepressant should be tailored to the patient, while involving the patient in the decision-making process. In general, the choice for the first- and second-line treatment will be a second-generation antidepressant. Recently, esketamine nasal spray (intranasal (IN) administration) was approved for patients with treatment-resistant MDD (TRD). A patient is diagnosed with TRD when having used two antidepressants in sufficient duration and adequate dose without sufficient effect. TRD is associated with a negative impact on quality of life, higher risk for hospitalisations and suicide, comorbidities, poorer social and occupational functioning and a high carer burden. The efficacy of intranasal use of esketamine has been demonstrated in MDD subjects with treatment-resistant symptoms but also in subjects with non-treatment resistant depression, and is approved by the FDA and EMA as a third-line treatment. Besides the registered esketamine nasal spray, which is not available in all countries to all patients because of the high costs, off-label utilization of (es)ketamine infusions (IV) is growing extensively over time to treat TRD. Research conducted so far indicates an unequivocal initial substantial response to (es)ketamine IV in MDD populations, regardless of whether or not patients suffer from treatment resistant MDD. However, until now, there has not been a study investigating this in a sufficiently large population. This may be a unique opportunity to potentially prevent patients progressing into a treatment resistant illness stage. The potential implications of the results of the current study are the prevention of unnecessary trials of ineffective treatments, reducing subject burden substantially, as well as a reduction of healthcare and societal costs.

Objective The primary objective is to compare the treatment response (baseline; visit 2 vs. end of treatment; visit 4), expressed as symptom severity at six weeks and changes in symptom severity from baseline, as measured through the Montgomery-Åsberg Depression Rating Scale (MADRS) under an early-intensified pharmacological treatment to that under treatment as usual, in subjects who had a first-time treatment failure of first-line treatment during the current episode of MDD.

Main trial endpoints Change in symptom severity total score from baseline (visit 2) to end of treatment (visit 4). This is measured using MADRS.

Secondary trial endpoints

  1. To compare changes in severity and improvement in global functioning assessed by the Clinical Global Impression Scale (CGI) between the two treatment arms.
  2. To compare changes in the levels of depression and anxiety between treatment arms.
  3. To compare changes in quality of life and functioning measures between treatment arms.
  4. To compare changes in cognitive performance between treatment arms.
  5. To compare the proportion of participants (EIPT vs. TAU) that is in symptomatic remission at visit 4.
  6. To compare presence of side effects between treatment arms.
  7. To compare use of concomitant medication between treatment arms.
  8. To compare premature discontinuation (timing and reason) between treatment arms.
  9. To compare changes in suicidal ideation between treatment arms.

Trial design The clinical study is an international, multicenter controlled, randomised, open label trial (with blinded raters), with a treatment duration of four weeks.

Trial population The aim is to recruit 418 subjects with major depressive disorder, without psychotic features. Male and female subjects, in- and out-patients, within the age range of 18 to 65 years old are eligible for participation. The main exclusion criteria are defined to protect the wellbeing of subjects, e.g. being pregnant or breastfeeding, subjects with previous failure on (es)ketamine, meeting any contraindications, or participants with a known intolerance to (es)ketamine.

Interventions

Subjects are randomised to treatment as usual (second-line treatment) or to the early-intensified pharmacological treatment (third-line treatment). Treatment per can be found in the table below:

Table 1. Overview of treatment randomisation per study sample. MDD sample Treatment as Usual (TAU) Switch to second-line antidepressant Early-Intensified Pharmacological Treatment (EIPT) Oral antidepressant plus esketamine nasal spray or esketamine IV or ketamine IV

Ethical considerations relating to the clinical trial including the expected benefit to the individual subject or group of subjects represented by the trial subjects as well as the nature and extent of burden and risks In the current study, clinical practice is mimicked as much as possible to maximize generalizability and for feasibility purposes. To this end, Summaries of Product Characteristics (SmPCs) are followed with regards to contraindications (implemented as exclusion criterion), safety measures and allowed combinations with other medications. Site visits and assessments are kept to a minimum to keep subject burden at an acceptable level, while meeting the objectives of the study. Blood samples for biomarker analyses are only collected when subjects provide consent; safety measures are performed as part of clinical routine.

Use of both EIPT and TAU medications implies that there is a risk of side effects. For TAU, these side effects are well-known, and would be no different from regular clinical practice. For EIPT, there are acute psychotropic effects of (es)ketamine which are considered side effects for this study, such as anxiety, delusional thoughts, dissociation and hallucinations (see IMPDs). In addition, increased blood pressure and heart rate, as well as dizziness and nausea are reported. These acute effect are transient and after 2 hours completely dissipated. Therefore, an observation period of 2 hours after every administration is implemented to monitor this closely. The potential side effects of all treatments are well-known and will be monitored during the study with a standardized side-effect scale (GASE), spontaneous reporting and the local standard procedure regarding other measures such as laboratory tests, physical examinations, ECGs. The results will be captured (as data) and reviewed for tolerability. Most of the tests that will be done as part of standard clinical care (lab tests, ECG, physical examination) for EIPT are also part of TAU.

A benefit of the study is that while ensuring that the tolerability and additional burden remains acceptable, the investigators expect that the larger effect in reducing symptom severity will justify the increase in burden relative to the TAU group. When participants are treated with the intense treatment in earlier stage of the illness (less trial and error before moving on to this treatment option), this is expected to result in a reduced burden of disease for subjects, expressed as less relapses, lower all-cause mortality, hospitalisations and job losses and improved quality of life, in addition to lower societal and healthcare costs as well as preventing patients from turning into a treatment-resistant treatment phase. Last, an advantage of participation could be that subjects will be more thoroughly followed and examined, and that therefore effects and side effects are measured and managed better.

IMPORTANT: the study was submitted to the European authorities before (see NCT05603104) and they requested to split this study into 3 studies (1 for each diagnostic category). The investigators have done this and created 3 new ClinicalTrials.gov studies as well, from which this is one for major depressive disorder. The ClinicalTrial.gov numbers for the other studies are NCT05958875 for INTENSIFY SZ and NCT05973786 for INTENSIFY BD. The site in the UK (London) followed the advice and will submit 3 separate protocols and are therefore included in the current record. However, Israel already submitted this as one protocol. Therefore, the investigators keep the old clinicaltrials.gov number for Israel (NCT05603104).

03

Conditions studied

  • Major Depressive Disorder
  • Treatment Resistant Depression

Keywords

  • Major Depressive Disorder
  • Treatment as usual
  • Early treatment-resistance
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In- or outpatients, at least 18 years of age up until 65.
  2. Being willing and able to provide written . Having a legal guardian to cosign is allowed. Informed consent will be signed at visit 1, before any study procedure.
  3. Female subjects of child bearing potential must use effective during the trial as per the requirements of the applicable SmPCs and should have a negative pregnancy test at visit 1 or 2 (before randomisation).
  4. Meeting diagnostic criteria for a primary diagnosis of major depressive disorder (without psychotic features), according to . The primary diagnosis will be confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2).
  5. Subject experiences a treatment failure due to lack of efficacy in the current episode, as confirmed by a CGI-I ≥3; perferably, this treatment is a pharmacotherapeutic agent for the primary DSM-5 diagnosis, and was prescribed for at least 4 weeks within an effective dose range as specified in the Summary of Product Characteristics (SmPCs).
  6. Subject and clinician intend to change pharmacotherapeutic treatment. However, other lines of treatment are allowed as well.
  7. A minimum symptom severity threshold needs to be present (moderate level; see below) and subject needs to experience functional impairment.

    • The minimum symptom severity threshold is a score of ≥20 on the Montgomery Åsberg Depression Rating Scale (MADRS)
    • Functional impairment is defined as a score of 5 or higher on any of the three scales of the Sheehan Disability Scale (SDS).

Exclusion criteria

Exclusion criteria:

  1. Being pregnant or breastfeeding.
  2. Subject has used (es)ketamine previously for the treatment of depressive symptoms.
  3. Subject has a known intolerance to (es)ketamine or to all TAU medication.
  4. Meeting any of the for (es)ketamine, or to all TAU medication options, as specified within the applicable SmPC, supported by abnormal values on local laboratory tests, (ECG) or physical examinations.
  5. Subject has participated in another clinical trial in which the subject received an experimental or drug or agent within 30 days before visit 1.
  6. Subject experiences any other significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the trial, or may influence the result of the trial, or the subject's ability to participate in the trial.
  7. Subjects with active suicidal ideation with some intent to act, without specific plan ("Yes" to question 4 of the Columbia-Suicide Severity Rating Scale (C-SSRS)) or active suicidal ideation with specific plan and intent ("Yes" to question 5 of the C-SSRS), followed by an assessment by the treating clinician who determines it is not safe for the subject to participate in the study
  8. Subject meets criteria for current substance use disorder, as confirmed by the Mini International Neuropsychiatric Interview (MINI v7.0.2). Nicotine dependency is allowed, as well as mild and moderate alcohol and/or cannabis use disorder (as defined by MINI v7.0.2). Severe alcohol and/or cannabis use disorder are not allowed.
  9. Subjects have not been committed to an institution by virtue of an order issued either by the judicial or the administrative authorities.
  10. Subjects dependent on the sponsor, investigator or trial site must be excluded from participation in advance.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
418 participants (estimated)

Study arms

  • Experimental
    Major Depressive Disorder EIPT: second-line antidepressant + esketamine nasal spray

    Major depressive disorder randomized to EIPT: Switch to second-line antidepressant + esketamine nasal spray or (es)ketamine infusion. Antidepressant: Compound, brand, dosage, frequency and duration up to the investigator's discretion (in accordance with SmPC). Esketamine nasal spray: 2 times per week for 4 weeks. Initial dose 28 mg, after that increases can be made with 28 mg per increase (up to 84 mg per week). This decision is up to the investigator's discretion (in accordance with SmPC). (Es)ketamine infusion: performed twice weekly for 4 weeks. Compound, brand up to the investigator's discretion (in accordance with SmPC).

    Drug: Esketamine Nasal Product · Drug: Ketamine Hydrochloride · Drug: Esketamine hydrochloride

  • Active comparator
    Major Depressive Disorder TAU: second-line antidepressant

    Subject with major depressive disorder, randomized to TAU: switch to second-line antidepressant. When randomized to second-line anti-depressants, this means participants will receive treatment as usual. The physician has the choice to administer any second-line anti-depressant. More specification is not possible, as this is a choice the physician makes with the participant based on the characteristic and preference of the participant (in line with standard clinical practice).

    Drug: Second-line Antidepressants

Interventions

06

What researchers measure

Primary outcomes

  1. Comparing the change in symptom severity on Montgomery Asberg Depression Rating Scale

    Change in symptom severity (EIPT vs. TAU) total score from baseline (visit 2) to end of treatment (visit 4). This is measured using the Montgomery Asberg Depression Rating Scale. Minimum score is 0, maximum score 60. A bigger mean change means a better outcome

    Time frame: 6 weeks

Secondary outcomes

  1. Compare proportion of participants that is in symptomatic remission

    Comparison of the proportion of participants (EIPT vs. TAU) that is in symptomatic remission at visit 4. Remission is defined as a Montgomery Asberg Depression Rating scale score of ≤ 12.

    Time frame: 6 weeks

  2. Compare the change in the severity and improvement CGI-S sub-scores

    To compare changes in the severity sub-score of the Clinical Global Impression Scale (CGI 2) between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2 versus visit 4). Higher scores indicate higher illness severity. Minimum score: 1, maximum score: 7

    Time frame: 6 weeks

  3. Compare the change in the severity and improvement CGI-I sub-scores

    To compare changes in the total improvement sub-score of the Clinical Global Impression Scale (CGI 2) between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2 versus visit 4). A higher score means lower treatment improvement. Minimum score: 1, maximum score: 7

    Time frame: 6 weeks

  4. Compare the changes in the levels of depression and anxiety

    To compare changes in the levels of depression and anxiety as assessed with the Hospital Anxiety and Depression Scale between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2 versus visit 4). Lower scores mean less depression and anxiety.

    Time frame: 6 weeks

  5. To compare changes in cognitive performance as measured through the Trail Making Test

    To compare changes in cognitive performance as measured through the Trail Making Test between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). A lower time to complete the test means better cognitive performance.

    Time frame: 6 weeks

  6. To compare the changes in cognitive performance as measured through the Rey Auditory Verbal Learning Test

    To compare changes in cognitive performance as measured through the Rey Auditory Verbal Learning Test between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). A higher scores means better cognitive performance.

    Time frame: 6 weeks

  7. To compare the changes in subjective cognitive performance as measured through the Perceived Deficits Questionnaire

    To compare changes in cognitive performance as measured through the Perceived Deficits Questionnaire between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). A higher scores means worse subjective cognitive performance.

    Time frame: 6 weeks

  8. To compare the changes in functioning on the Leuven Affective and Pleasure Scale

    To compare changes in the functioning measure, Leuven Affective and Pleasure Scale, between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). A higher scores means worse functioning. Minimum score: 0, Maximum score: 160

    Time frame: 6 weeks

  9. To compare the changes in functioning on the Sheehan Disability Scale

    To comparechanges in the functioning measure,Sheehan Disability Scale, between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). A higher scores means worse functioning. Minimum score: 0, maximum score 30.

    Time frame: 6 weeks

  10. To compare the changes in quality of life measure, Quality of Life Enjoyment and Satisfaction Questionnaire Short Form

    To compare changes in quality of life measure, Quality of Life Enjoyment and Satisfaction Questionnaire Short Form between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). A higher scores means better quality of life. Minimum score: 16, maximum score: 80.

    Time frame: 6 weeks

  11. To compare the changes of participants in quality of life measure, Quality of Life Scale -100, subscale inner tension

    To compare changes in quality of life measure, Quality of Life Scale -100, subscale inner tension between the two treatment arms over the four weeks treatment period (visit 2 versus visit 4). This is a dichotomous scale (unsatisfactory or satisfactory). More 'satisfactory' answers means higher quality of life.

    Time frame: 6 weeks

  12. To compare the frequency of occurrence of side effects between the two treatment arms.

    To compare presence of side effects as measured through General Assessment of Side Effects Scale and reported spontaneously between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2 versus visit 4). Higher scores means more side effects. Minimum score: 0 side effects, maximum score: 38 side effects.

    Time frame: 6 weeks

  13. To compare the proportion of participants using concomitant medication between the two treatment arms.

    To compare use of concomitant medication between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2 versus visit 4) effects.

    Time frame: 6 weeks

  14. To compare the proportion of participants who prematurely discontinue between the two treatment arms.

    To compare premature discontinuation between the two treatment arms (EIPT/TAU) over the four week treatment period (visit 2 versus visit 4).

    Time frame: 6 weeks

  15. To compare the reason of participants that prematurely treatment discontinue the study between the two treatment arms.

    To compare the difference in reason of participants that prematurely discontinue the study treatment between the two treatment arms.

    Time frame: 6 weeks

  16. To compare changes in suicidal ideation between treatment arms.

    Changes on the Columbia-Suicide Severity Rating Scale (C-SSRS) throughout the study; EIPT vs TAU. Higher scores means higher suicidal ideation. The maximum score is 5.

    Time frame: 6 weeks.

07

Study locations

8 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2028, 45 months after the start.

Of 123 phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 36. This study's planned 45 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2023
First posted
Aug 3, 2023
StartActual
Aug 31, 2024
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05973851
Lead sponsor
Dr. Inge Winter
Collaborators
Universität Münster
Responsible party
Dr. Inge Winter (Principal Investigator, UMC Utrecht) — Sponsor-investigator
First posted
Aug 3, 2023
Start date
Aug 31, 2024
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 26, 2025

Study contacts

Inge Winter, Dr.
Contact
i.winter@umcutrecht.nl
+31875553227
Cynthia Okhuijsen-Pfeifer, Dr.
Contact
c.pfeifer@umcutrecht.nl
+31875553227

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Escitalopram · Ketamine · Esketamine

Start the discussion